Best in class antiviral antibodies from cognate recombinant antibody repertoires of human donors

This talk, “Best in class antiviral antibodies from cognate recombinant antibody repertoires of human donors” was given during the 2023 PEGS Europe conference in Lisbon, Portugal by Matthias Hillenbrand from Memo Therapeutics AG. Matthias Hillenbrand is the Head of Infectious Diseases at Memo Therapeutics, an ETH spin-off, overseeing antibody discovery campaigns that yielded potent nAbs against BKV, SARS-CoV-2 and HCMV.
Memo Therapeutics AG developed Dropzylla®, an antibody discovery platform based on a high-throughput conversion of B cell repertoires into immortalized mammalian-display biobanks. Deploying the platform, Memo Therapeutics AG identified potent nAbs from convalescent donors against BK virus and SARS-CoV-2, AntiBKV being in a pivotal phase II/III clinical trial with FDA fast-track designation. Currently, the identification of a set of nAbs against HCMV is ongoing, a severe threat to immunosuppressed individuals.
Learn more about the latest results of Memo Therapeutics AG´s research on identifying potent nAbs against BK Virus, SARS-CoV-2 and HCMV in this exciting talk.